📊 ENZN Key Takeaways
Is Enzon Pharmaceuticals, Inc.. (ENZN) a Good Investment?
Enzon Pharmaceuticals is in severe financial distress with negative stockholders' equity of -$2.5M, indicating liabilities exceed assets attributable to shareholders. The company generated only $26K in revenue while burning $3.0M in operating cash flow, demonstrating a non-viable business model with massive operating losses (-$5.3M) and negative net income of -$3.4M. Despite holding $42.6M in cash, the company is consuming capital at an unsustainable rate with no clear path to profitability or revenue growth.
Enzon Pharmaceuticals shows extremely weak operating fundamentals: revenue is effectively nonexistent at $26K, operating losses remain severe, and free cash flow is negative. While the company has an unusually large cash balance and minimal liabilities relative to assets, the business currently lacks evidence of a viable, growing operating engine, so the balance sheet strength looks more like runway than fundamental quality.
Why Buy Enzon Pharmaceuticals, Inc.. Stock? ENZN Key Strengths
- Substantial cash position of $42.6M provides near-term runway
- Excellent liquidity ratios (58.57x current ratio) with minimal short-term obligations
- No long-term debt burden
- Very strong liquidity with $42.57M in cash and current ratio of 58.57x
- Net loss improved year over year, indicating some expense containment
- Low absolute liabilities reduce near-term financial distress risk
ENZN Stock Risks: Enzon Pharmaceuticals, Inc.. Investment Risks
- Negative stockholders' equity of -$2.5M indicates balance sheet insolvency
- Virtually no revenue generation ($26K) with massive operating losses (-$5.3M)
- Negative operating cash flow of -$3.0M per period indicates unsustainable cash burn
- Deteriorating net income trend (-$3.4M) with negative net margin of -13,111%
- Zero insider activity in last 90 days suggests lack of confidence from management
- Revenue base is negligible and showed no year-over-year growth, signaling poor business traction
- Persistent operating and free cash flow losses continue to erode economic value
- Negative stockholders equity raises concerns about balance sheet quality and long-term sustainability
Key Metrics to Watch
- Revenue generation and path to positive operating income
- Monthly cash burn rate and runway remaining
- Stockholders equity recovery and balance sheet stabilization
- Quarterly cash burn relative to the $42.57M cash balance
- Whether revenue becomes material and operating losses narrow on a sustained basis
Enzon Pharmaceuticals, Inc.. (ENZN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 58.57x current ratio provides a solid financial cushion.
ENZN Profit Margin, ROE & Profitability Analysis
ENZN vs Healthcare Sector: How Enzon Pharmaceuticals, Inc.. Compares
How Enzon Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Enzon Pharmaceuticals, Inc.. Stock Overvalued? ENZN Valuation Analysis 2026
Based on fundamental analysis, Enzon Pharmaceuticals, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Enzon Pharmaceuticals, Inc.. Balance Sheet: ENZN Debt, Cash & Liquidity
ENZN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Enzon Pharmaceuticals, Inc..'s revenue has declined by 96% over the 5-year period, indicating business contraction. The most recent EPS of $-0.01 indicates the company is currently unprofitable.
ENZN Revenue Growth, EPS Growth & YoY Performance
ENZN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $26.0K | $254.0K | $0.00 |
| Q2 2025 | $26.0K | $276.0K | $0.00 |
| Q3 2024 | $26.0K | $183.0K | $0.00 |
| Q2 2024 | $26.0K | $183.0K | $0.00 |
| Q1 2024 | N/A | $197.0K | $0.00 |
| Q3 2023 | N/A | -$15.0K | $0.00 |
| Q2 2023 | N/A | $183.0K | $0.00 |
| Q1 2023 | N/A | $197.0K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Enzon Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
ENZN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Enzon Pharmaceuticals, Inc.. (CIK: 0000727510)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ENZN
What is the AI rating for ENZN?
Enzon Pharmaceuticals, Inc.. (ENZN) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 93% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ENZN's key strengths?
Claude: Substantial cash position of $42.6M provides near-term runway. Excellent liquidity ratios (58.57x current ratio) with minimal short-term obligations. ChatGPT: Very strong liquidity with $42.57M in cash and current ratio of 58.57x. Net loss improved year over year, indicating some expense containment.
What are the risks of investing in ENZN?
Claude: Negative stockholders' equity of -$2.5M indicates balance sheet insolvency. Virtually no revenue generation ($26K) with massive operating losses (-$5.3M). ChatGPT: Revenue base is negligible and showed no year-over-year growth, signaling poor business traction. Persistent operating and free cash flow losses continue to erode economic value.
What is ENZN's revenue and growth?
Enzon Pharmaceuticals, Inc.. reported revenue of $26.0K.
Does ENZN pay dividends?
Enzon Pharmaceuticals, Inc.. pays dividends, with $1.3M distributed to shareholders in the trailing twelve months.
Where can I find ENZN SEC filings?
Official SEC filings for Enzon Pharmaceuticals, Inc.. (CIK: 0000727510) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ENZN's EPS?
Enzon Pharmaceuticals, Inc.. has a diluted EPS of $-0.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ENZN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Enzon Pharmaceuticals, Inc.. has a STRONG SELL rating with 93% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ENZN stock overvalued or undervalued?
Valuation metrics for ENZN: ROE of N/A (sector avg: 15%), net margin of -13,111.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ENZN stock in 2026?
Our dual AI analysis gives Enzon Pharmaceuticals, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ENZN's free cash flow?
Enzon Pharmaceuticals, Inc..'s operating cash flow is $-3.0M, with capital expenditures of $0.0. FCF margin is -11,576.9%.
How does ENZN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -13,111.5% (avg: 12%), ROE N/A (avg: 15%), current ratio 58.57 (avg: 2).